BSX·Boston Scientific Corporation

Boston Scientific management has reaffirmed confidence in achieving its financial guidance, suggesting recent stock declines may be overdone. This assurance, following a recent fireside chat, was accompanied by a reiterated positive outlook for key products, including pulsed-field ablation and Watchman. The company's operational momentum is underpinned by robust revenue growth, with Q4 results exceeding analyst expectations. Investors should watch for continued execution on these product lines and the company's ability to translate this operational strength into sustained financial performance.